EMA Recommends Extension of Indications for Sugemalimab By Ogkologos - October 28, 2025 252 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns monotherapy for the treatment of unresectable stage III NSCLC with no genomic alterations Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR Low-Dose Adjuvant Aspirin Decreases Incidence of Recurrence Among Patients with Resected... September 30, 2025 Mom Finding Out Baby’s Gender Uncovers Rare Condition When Doctors See... November 7, 2019 Rare Identical Twins Born With Different Body Sizes Get Mistaken For... December 13, 2019 AI Model Identifies How Every Country Can Improve Its Cancer Outcomes January 14, 2026 Load more HOT NEWS Fructose Fuels Cancer Growth Indirectly, Lab Study Finds Breast-Cancer Mom Is Living On 84 Pence As She Fights For... EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib ELCC 2015 News: ‘Real-World’ EGFR Mutation Frequency Results From a Large...
